Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2022  >  38(8): 687-695
YIN De-fei, WEI Xiu-nan, LIU Jia-hui, CHENG Yan, LIU Tong, CHI Li-li. Clinical Efficacy and Mechanism of Lichang Beverage in the Treatment of Diarrhea-Type Irritable Bowel Syndrome with Liver Depression and Spleen Deficiency[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(8): 687-695. doi: 10.14148/j.issn.1672-0482.2022.0687
Citation: YIN De-fei, WEI Xiu-nan, LIU Jia-hui, CHENG Yan, LIU Tong, CHI Li-li. Clinical Efficacy and Mechanism of Lichang Beverage in the Treatment of Diarrhea-Type Irritable Bowel Syndrome with Liver Depression and Spleen Deficiency[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(8): 687-695. doi: 10.14148/j.issn.1672-0482.2022.0687
shu

Clinical Efficacy and Mechanism of Lichang Beverage in the Treatment of Diarrhea-Type Irritable Bowel Syndrome with Liver Depression and Spleen Deficiency

doi: 10.14148/j.issn.1672-0482.2022.0687
  • 1.

    The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China

  • 2.

    School of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China

  • 3.

    The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China

  • Received Date: 2022-02-26
    Available Online: 2022-08-05
    Abstract
  •   OBJECTIVE  To observe the clinical efficacy of Lichang beverage in the treatment of diarrhea-type irritable bowel syndrome (IBS-D) based on the bacteria-brain-intestine axis and its effects on serum brain-gut peptide and intestinal flora, and to explore the possible mechanism of efficacy.  METHODS  A total of 66 IBS-D patients with liver depression and spleen deficiency were randomly divided into the Chinese medicine group (44 patients) and the western medicine group (22 patients) in a 2 ∶ 1 ratio. In the Chinese medicine group, Lichang beverage was given orally. However, the patients in the western medicine group were administrated with Bifico combination with Dicetel. The treatment course lasted four weeks. Besides, the changes in the IBS-SSS scores of both groups were evaluated before treatment, as well as after two weeks and four weeks of treatment. The changes in the traditional Chinese medicine (TCM) syndrome scores of both groups were observed before and after treatment. In addition, the expression levels of serum brain-gut peptide indexes [substance P (SP) and serotonin (5-HT)] and the composition of intestinal flora were measured.  RESULTS  The IBS-SSS scores of both groups were reduced significantly after two weeks and four weeks of treatment (P < 0.01), but the results in the Chinese medicine group were better than those in the western medicine group (P < 0.01). After four weeks of treatment, the total TCM syndrome scores of both groups were reduced significantly (P < 0.01), while the results in the Chinese medicine group were better than those in the western medicine group (P < 0.01). In addition, the clinical healing rate and total effective rate of the Chinese medicine group were higher than those of the western medicine group (P < 0.05, P < 0.01). After treatment, the serum SP level in both groups were reduced significantly (P < 0.05), and the serum 5-HT level in the Chinese medicine group were reduced notably (P < 0.01), but there was no significant difference between the two groups (P>0.05). The α diversity analysis indicated that the richness of intestinal flora in both groups decreased to different degrees after treatment (P < 0. 05, P < 0.01), and the diversity of flora in the western medicine group was reduced compared with that before (P < 0. 05), while there was no significant difference in the Chinese medicine group (P>0. 05). The PCoA analysis showed that the composition of microbial community in both groups changed significantly (P < 0. 05), and there were significant differences between groups (P < 0.01). Among them, the biomarkers with significant advantages after treatment in the Chinese medicine group were Clostridium_sensu_stricto_1 and Bacteroides_plebeius. However, the Biomarkers with significant advantages after treatment in the western medicine group were ruminococcus_gnavus_group. The functional prediction of the flora suggested that the main pathway of IBS-D treatment by Lichang beverage was glucose metabolism-related. Besides, no drug-related adverse reactions were observed in either group during the treatment course.  CONCLUSION  The efficacy of Chinese herbal medicine compound — Lichang beverage in treating IBS-D with liver depression and spleen deficiency is accurate and safe. Its mechanism may be related to the regulation of serum brain-gut peptide level, adjustment of intestinal flora structure, correction of flora imbalance, and regulation of glucose metabolism-related flora.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    ENCK P, AZIZ Q, BARBARA G, et al. Irritable bowel syndrome[J]. Nat Rev Dis Primers, 2016, 2: 16014. doi: 10.1038/nrdp.2016.14
    [2]
    XIONG LS, CHEN MH, CHEN HX, et al. A population-based epidemiologic study of irritable bowel syndrome in Guangdong province[J]. Nat Med J Chin, 2004, 84(4): 278-281.
    [3]
    方秀才. 肠易激综合征发病机制研究进展[J]. 胃肠病学, 2020, 25(6): 321-325. doi: 10.3969/j.issn.1008-7125.2020.06.001

    FANG XC. Advances in study on pathogenesis of irritable bowel syndrome[J]. Chin J Gastroenterol, 2020, 25(6): 321-325. doi: 10.3969/j.issn.1008-7125.2020.06.001
    [4]
    MARGOLIS KG, CRYAN JF, MAYER EA. The microbiota-gut-brain axis: From motility to mood[J]. Gastroenterology, 2021, 160(5): 1486-1501. doi: 10.1053/j.gastro.2020.10.066
    [5]
    BENNETT G, TALLEY NJ. Irritable bowel syndrome in the elderly[J]. Best Pract Res Clin Gastroenterol, 2002, 16(1): 63-76. doi: 10.1053/bega.2001.0266
    [6]
    熊理守, 彭穗, 陈为, 等. 肠易激综合征患者的就医行为及其影响因素[J]. 中华全科医师杂志, 2010, 9(12): 829-832. doi: 10.3760/cma.j.issn.1671-7368.2010.12.006

    XIONG LS, PENG S, CHEN W, et al. Correlates of health-care seeking behavior in patients with irritable bowel syndrome[J]. Chin J Gen Pract, 2010, 9(12): 829-832. doi: 10.3760/cma.j.issn.1671-7368.2010.12.006
    [7]
    杨焱麟, 陈敏, 周彦妮, 等. P物质与肝郁脾虚型腹泻型肠易激综合征关系及中医药调控的研究进展[J]. 中华中医药学刊, 2021, 39(9): 82-85. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202109022.htm

    YANG YL, CHEN M, ZHOU YN, et al. Research progress of substance P, liver stagnation and spleen deficiency type of IBS-D and traditional Chinese medicine regulation[J]. Chin Arch Tradit Chin Med, 2021, 39(9): 82-85. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202109022.htm
    [8]
    陈立亚, 刘畅, 汪芳裕. 肠易激综合征与肠道微生态及脑-肠轴关系的研究进展[J]. 胃肠病学和肝病学杂志, 2017, 26(5): 491-495. doi: 10.3969/j.issn.1006-5709.2017.05.004

    CHEN LY, LIU C, WANG FY. Research progress of the relationship of gut microbiota, gut-brain axis with irritable bowel syndrome[J]. Chin J Gastroenterol Hepatol, 2017, 26(5): 491-495. doi: 10.3969/j.issn.1006-5709.2017.05.004
    [9]
    TAP J, DERRIEN M, TÖRNBLOM H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome[J]. Gastroenterology, 2017, 152(1): 111-123. doi: 10.1053/j.gastro.2016.09.049
    [10]
    LABUS JS, OSADCHIY V, HSIAO EY, et al. Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis[J]. Microbiome, 2019, 7: 45. doi: 10.1186/s40168-019-0656-z
    [11]
    BARBARA G, FEINLE-BISSET C, GHOSHAL UC, et al. The intestinal microenvironment and functional gastrointestinal disorders[J]. Gastroenterology, 2016, 150(6): 1305-1318. doi: 10.1053/j.gastro.2016.02.028
    [12]
    李兆龙, 张有成, 韩文峰, 等. 粪菌移植治疗肠易激综合征研究进展[J]. 中国微生态学杂志, 2021, 33(2): 231-235. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS202102023.htm

    LI ZL, ZHANG YC, HAN WF, et al. Advances in the treatment of irritable bowel syndrome with fecal bacteria transplantation[J]. Chin J Microecol, 2021, 33(2): 231-235. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS202102023.htm
    [13]
    赵鲁卿, 张声生, 卢小芳, 等. 疏肝健脾方对腹泻型肠易激综合征大鼠的治疗作用及对肥大细胞、5-HT通路的影响[J]. 中国中西医结合消化杂志, 2017, 25(8): 589-594. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201708009.htm

    ZHAO LQ, ZHANG SS, LU XF, et al. Effect of Shugan Jianpi formula on mast cell and 5-HT pathway in D-IBS rats[J]. Chin J Integr Tradit West Med Dig, 2017, 25(8): 589-594. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201708009.htm
    [14]
    孙大娟, 由新鹏, 迟莉丽. 基于"土中泻木"理论论治肝郁脾虚型腹泻型肠易激综合征疗效观察及机制探讨[J]. 南京中医药大学学报, 2020, 36(2): 193-196. http://xb.njucm.edu.cn/article/id/zr20200213

    SUN DJ, YOU XP, CHI LL. Discussion on curative effect and mechanism of treating diarrhea predominant irritable bowel syndrome with liver-stagnation and spleen-deficiency based on"purging wood from earth"[J]. J Nanjing Univ Tradit Chin Med, 2020, 36(2): 193-196. http://xb.njucm.edu.cn/article/id/zr20200213
    [15]
    孙大娟, 梁峻尉, 闫华, 等. 腹泻型肠易激综合征患者直肠动力学变化及中药复方的干预作用[J]. 中国中医药科技, 2019, 26(3): 423-424. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY201903044.htm

    SUN DJ, LIANG JW, YAN H, et al. Rectal dynamic change in patients with diarrhea-predominant irritable bowel syndrome and that intervention effect of chinese herbal compound[J]. Chin J Tradit Med Sci Technol, 2019, 26(3): 423-424. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY201903044.htm
    [16]
    孙大娟, 迟莉丽, 梁峻尉, 等. 焦虑状态与IBS-D的相关性研究及中药复方的干预作用[J]. 光明中医, 2018, 33(17): 2473-2475. doi: 10.3969/j.issn.1003-8914.2018.17.004

    SUN DJ, CHI LL, LIANG JW, et al. Study on the correlation between anxiety state and IBS-D and intervention effect of compound traditional Chinese medicine[J]. Guangming J Chin Med, 2018, 33(17): 2473-2475. doi: 10.3969/j.issn.1003-8914.2018.17.004
    [17]
    梁峻尉, 白文筠, 迟莉丽, 等. 加味理肠饮对腹泻型肠易激综合征大鼠5-HT、NPY及肥大细胞的影响[J]. 山东中医药大学学报, 2018, 42(4): 346-350. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYX201804023.htm

    LIANG JW, BAI WJ, CHI LL, et al. Effects of Jiawei lichang decoction on 5-HT, NPY, and mast cells in rats with diarrhea-predominant irritable bowel syndrome[J]. J Shandong Univ Tradit Chin Med, 2018, 42(4): 346-350. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYX201804023.htm
    [18]
    梁峻尉, 白文筠, 迟莉丽, 等. 中药加味理肠饮对腹泻型肠易激综合征大鼠SP、VIP、CORT含量的影响[J]. 中医药学报, 2018, 46(3): 54-57. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXB201803014.htm

    LIANG JW, BAI WY, CHI LL, et al. Effect of modified Jiawei lichang Yin on SP, VIP and CORT in IBS rats of diarrhea type[J]. Acta Chin Med Pharmacol, 2018, 46(3): 54-57. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXB201803014.htm
    [19]
    王雨宁, 徐畅, 邹康, 等. 临床试验中适应性随机化的应用[J]. 中国循证医学杂志, 2020, 20(5): 616-620. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ202005017.htm

    WANG YN, XU C, ZOU K, et al. Application of adaptive randomization in clinical trials[J]. Chin J Evid Based Med, 2020, 20(5): 616-620. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ202005017.htm
    [20]
    DROSSMAN DA, HASLER WL. Rome Ⅳ—functional GI disorders: Disorders of gut-brain interaction[J]. Gastroenterology, 2016, 150(6): 1257-1261. doi: 10.1053/j.gastro.2016.03.035
    [21]
    中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 134-151.

    Guiding Principles for Clinical Research of New Chinese Medicine: Trial Implementation[M]. Beijing: China medical science press, 2002: 134-151.
    [22]
    张声生, 魏玮, 杨俭勤. 肠易激综合征中医诊疗专家共识意见(2017)[J]. 中医杂志, 2017, 58(18): 1614-1620. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201718024.htm

    ZHANG SS, WEI W, YANG JQ. Consensus of TCM diagnosis and treatment experts on irritable bowel syndrome(2017)[J]. J Tradit Chin Med, 2017, 58(18): 1614-1620. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201718024.htm
    [23]
    卞立群. 肠安Ⅰ号方治疗IBS-D的临床疗效评价暨临床疗效评价指标的比较研究[D]. 北京: 中国中医科学院, 2011.

    BIAN LQ. Clinical effect evaluation of Chang'anyihao decoction in treating IBS-D and research of IBS clinical effect assessment indices[D]. Beijing: China Academy of Chinese Medical Sciences, 2011.
    [24]
    GROS M, GROS B, MESONERO JE, et al. Neurotransmitter dysfunction in irritable bowel syndrome: Emerging approaches for management[J]. J Clin Med, 2021, 10(15): 3429. doi: 10.3390/jcm10153429
    [25]
    MISHIMA Y, ISHIHARA S. Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome[J]. Int J Mol Sci, 2021, 22(19): 10235. doi: 10.3390/ijms221910235
    [26]
    胡莹, 郑依玲, 梅全喜, 等. 痛泻要方破壁饮片对腹泻型肠易激综合征大鼠脑肠肽的影响[J]. 中药材, 2020, 43(7): 1726-1731. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCA202007036.htm

    HU Y, ZHENG YL, MEI QX, et al. Effect of Tongxieyaofang ultrafine granular powder on intestine propulsion and vasoactive intestinal peptide in diarrhea-predominant of irritable bowel syndrome model rats[J]. J Chin Med Mater, 2020, 43(7): 1726-1731. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCA202007036.htm
    [27]
    BOSI A, BANFI D, BISTOLETTI M, et al. Tryptophan metabolites along the microbiota-gut-brain axis: An interkingdom communication system influencing the gut in health and disease[J]. Int J Tryptophan Res, 2020, 13: 1178646920928984.
    [28]
    KONG C, GAO RY, YAN XB, et al. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet[J]. Nutrition, 2019, 60: 175-184. doi: 10.1016/j.nut.2018.10.002
    [29]
    PÉREZ-BURILLO S, PASTORIZA S, FERNáNDEZ-ARTEAGA A, et al. Spent coffee grounds extract, rich in mannooligosaccharides, promotes a healthier gut microbial community in a dose-dependent manner[J]. J Agric Food Chem, 2019, 67(9): 2500-2509. doi: 10.1021/acs.jafc.8b06604
    [30]
    XIAO L, LIU Q, LUO M, et al. Gut microbiota-derived metabolites in irritable bowel syndrome[J]. Front Cell Infect Microbiol, 2021, 11: 729346. doi: 10.3389/fcimb.2021.729346
    [31]
    HALMOS EP, POWER VA, SHEPHERD SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome[J]. Gastroenterology, 2014, 146(1): 67-75. doi: 10.1053/j.gastro.2013.09.046
    [32]
    CREMON C, CARINI G, WANG BX, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome[J]. Am J Gastroenterol, 2011, 106(7): 1290-1298. doi: 10.1038/ajg.2011.86
    [33]
    唐洪梅, 涂星, 柴玉娜, 等. 两种亚型肠易激综合征中氨基酸神经递质及其受体变化[J]. 世界华人消化杂志, 2014, 22(30): 4559-4565. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201430002.htm

    TANG HM, TU X, CHAI YN, et al. Contents of amino acid neurotransmitters and expression of γ-aminobutyric acid receptor in two subtypes of irritable bowel syndrome[J]. World Chin J Dig, 2014, 22(30): 4559-4565. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201430002.htm
    [34]
    赵滢. 抗生素诱导小鼠菌群变化与宿主代谢组相关性的研究[D]. 武汉: 华中科技大学, 2013.

    ZHAO Y. Antibiotics-induced mice microbial alteration and their relationship with host metabolic profiles[D]. Wuhan: Huazhong University of Science and Technology, 2013.
    [35]
    CHAVES FILHO AJM, LIMA CNC, VASCONCELOS SMM, et al. IDO chronic immune activation and tryptophan metabolic pathway: A potential pathophysiological link between depression and obesity[J]. Prog Neuro Psychopharmacol Biol Psychiatry, 2018, 80: 234-249. doi: 10.1016/j.pnpbp.2017.04.035
    [36]
    HATA T, ASANO Y, YOSHIHARA K, et al. Regulation of gut luminal serotonin by commensal microbiota in mice[J]. PLoS One, 2017, 12(7): e0180745. doi: 10.1371/journal.pone.0180745
    [37]
    ALEMI F, POOLE DP, CHIU J, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice[J]. Gastroenterology, 2013, 144(1): 145-154. doi: 10.1053/j.gastro.2012.09.055
    [38]
    REIGSTAD CS, SALMONSON CE, RAINEY JF, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells[J]. FASEB J, 2015, 29(4): 1395-1403. doi: 10.1096/fj.14-259598
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (210) PDF downloads(30) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return